摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-乙基-1H-苯并咪唑-2-磺酸 | 90331-19-4

中文名称
1-乙基-1H-苯并咪唑-2-磺酸
中文别名
1-乙基-2-苯并咪唑磺酸;1-乙基苯并咪唑-2-磺酸
英文名称
1-ethylbenzimidazole-2-sulfonic acid
英文别名
1-ethyl-1H-benzimidazole-2-sulfonic acid
1-乙基-1H-苯并咪唑-2-磺酸化学式
CAS
90331-19-4
化学式
C9H10N2O3S
mdl
MFCD00458807
分子量
226.256
InChiKey
CPFYRNMZRZTXRQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.222
  • 拓扑面积:
    80.6
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2933990090

SDS

SDS:cba4e897f9e6d385d43fb7d7ea19a5dd
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • IDO Inhibitors
    申请人:Mautino Mario
    公开号:US20110053941A1
    公开(公告)日:2011-03-03
    Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.
    目前提供以下方法:(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用,从而调节吲哚胺2,3-二氧化酶的活性;(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者,包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量;(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况,包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量;(d) 增强抗癌治疗的有效性,包括给予抗癌剂和本文中描述的化合物;(e) 治疗与癌症相关的肿瘤特异性免疫抑制,包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量;(f) 治疗与传染病相关的免疫抑制,例如HIV-1感染,包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
  • Synthesis and some conversions of N-substituted benzimidazole-2-sulfonic acids
    作者:L. N. Divaeva、T. A. Kuzmenko、A. S. Morkovnik、V. N. Komissarov
    DOI:10.1007/s10593-006-0112-4
    日期:2006.4
  • Synthesis and antitrichinellosis activity of some bis(benzimidazol-2-yl)amines
    作者:Anelia Ts. Mavrova、Pavletta Denkova、Yordan A. Tsenov、Kameliya K. Anichina、Dimitar I. Vutchev
    DOI:10.1016/j.bmc.2007.06.017
    日期:2007.9
    Novel bis(benzimidazol-2-yl)a mines were synthesized using two methods and studied for antitrichinellosis activity. DFT calculations were performed in order to determine the geometry of molecules. All derivatives of 2-aminobenzimidazole exhibited higher activity in vitro against Trichinella spiralis larvae in regard to the activity of albendazole, moreover compounds 4f-i manifested antitrichinellosis effect, which surpassed five times the activity of albendazole. The in vivo screening of intestinal phase of the T spiralis revealed 100% effectiveness of compounds 4g-i at oral dosages of 50 and 100 mg/kg mw, while albendazole possesses 100% efficacy only at a dose of 100 mg/kg mw. (c) 2007 Elsevier Ltd. All rights reserved.
  • Reduction of benzimidazole-2-sulfonic acids
    作者:I. I. Popov、S. L. Boroshko、B. A. Tertov
    DOI:10.1007/bf00506299
    日期:1984.2
  • XIMIYA GETEROTSIKL. SOEDIN., 1984, N 2, 266-267
    作者:
    DOI:——
    日期:——
查看更多